Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, the investigators are interested to know if lower doses of Primaquine together with dihydroartemisinin-piperaquine can produce a similar effect of clearing both sexual and asexual parasites in asymptomatic carriers compared to the recommended dose of primaquine but with a decreased risk of haemolysis.

Children (> 1 year) and adults with normal Glucose-6-phosphate dehydrogenase enzyme levels but with asexual Plasmodium falciparum parasites on the day of screening will be invited to take part in this study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: London School of Hygiene and Tropical Medicine; Medical Research Council Unit, The Gambia
• Treatments: Dihydroartemisinin; Piperaquine; Primaquine

Criteria

Inclusion Criteria:

Age ≥1 year

• Weight >10 Kg

• P. falciparum mono-infection, density of at least 20 parasites/μL

• Axillary temperature < 37.5ºC

• Resident in the study area and willingness to reside for the duration of the study

• Written informed consent (plus an assent in children >12years of age)

Exclusion Criteria:

• G6PD Deficiency Haemoglobin <8g/dl

• Known allergy to any of the study medications

• Known Pregnancy or breastfeeding

• Clear/documented history of anti-malarial treatment 2 weeks before contact with study team

• History of blood transfusion in the previous 3 months

• Any chronic or acute conditions that might interfere with the study as judged by the research clinician

• History of sickle cell anaemia